Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Solvay and INEOS Join Forces to Create a World-Class PVC Producer

Published: Friday, May 10, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
Signature of a letter of intent to create a 50-50 joint venture with combined sales of EUR 4.3 bn.

Solvay and INEOS have announced that they have signed a Letter of Intent (LOI) to combine their European chlorvinyls activities in a proposed 50-50 joint venture.

The combination would form a polyvinyl chloride (PVC) producer ranking among the top three worldwide. It would build on the strengths of both our companies’ industrial assets, the skills of our teams and the complementarity of our geographical presence in order to enhance competitiveness.

The joint venture would have pro-forma net sales of EUR 4.3 billion and REBITDA of EUR 257 million, based on 2012 figures.

The combined business would have around 5,650 employees in 9 countries and would pool each company’s assets across the entire chlorvinyls chain.

This includes PVC, which is the third most-used plastic in the world, caustic soda and chlorine derivatives. RusVinyl, Solvay’s Russian joint venture in chlorvinyls with Sibur, is excluded from the transaction.

“This proposed partnership is an ambitious and value-creating industrial project. We want to create a worldclass player that will benefit from the high-quality assets of both companies. The joint venture will improve the competitiveness of its operations in a very challenging environment regarding feedstock and energy costs in Europe. We are convinced that this is the right project to secure, for the long term, the development of Solvay’s European chlorvinyls activities, of its employees and its plants,” says Jean-Pierre Clamadieu, CEO of Solvay.

Clamadieu continued, “Furthermore, this transaction would substantially change our portfolio of activities and allow us to accelerate Solvay’s transformation into a chemical group focused on growth and high-margin businesses.”

“This agreement will result in the creation of a truly competitive and sustainable business that will provide significant benefit to customers such as reliable access to PVC,” said Jim Ratcliffe, Chairman, INEOS AG.

Ratcliffe continued, “The newly combined business, which will be of world scale, will be able to better respond to rapidly changing European markets and to match increasing competition from global producers."

The joint venture would generate significant synergies thanks to:
• shared best practices that improve production processes, particularly to optimize energy consumption;
• streamlined product mix and increased specialization of plants;
• optimized raw material and energy purchases and usage;
• reduced logistics and transport costs;
• and combined marketing and sales forces.

Solvay would contribute its vinyl activities, which are part of Solvin, as well as its Chlor Chemicals business, spread across seven fully integrated production sites in Europe. These sites include five electrolysis units converted into more energy efficient membrane technology, which supports sustainable production of PVC.

Kerling, the subsidiary of INEOS and the largest PVC producer in Europe, would contribute its chlorvinyls and related businesses that include three modern and large-scale membrane electrolysis units. These assets are based on ten sites in seven European countries.

The LOI provides exit mechanisms under which INEOS would acquire Solvay’s 50% interest in the joint venture for a value based on a mid-cycle REBITDA multiple of 5.5x.

The exit arrangements would have to be exercised between four and six years from the joint venture’s formation, after which INEOS would be the sole owner of the business.

Solvay would be entitled to receive upfront cash payments of EUR 250 million upon completion of the transaction.

The proposed transaction is subject to the applicable information/consultation procedures with employee representatives in the countries involved.

After completion of such procedures, the parties would enter into legally-binding agreements that would contain customary closing conditions, including anti-trust approval from the relevant authorities.

Until completion of the transaction, the occurrence and timing of which is dependent on such approval and procedures, Solvay and INEOS will continue to run their PVC businesses separately.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with polycystic ovary syndrome (PCOS), a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
How Cancer Spreads in the Body
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!